CASI Pharmeceuticals

EVOMELA

EVOMELA

EVOMELA® (melphalan) for Injection is a new intravenous formulation of melphalan being investigated by our licensor in the multiple myeloma transplant setting. The formulation avoids the use of propylene glycol, which is used as a co-solvent in the current formulation of melphalan and has been reported to cause renal and cardiac side-effects that limit the ability to deliver higher quantities of intended therapeutic compounds. The use of Captisol technology to reformulate melphalan is anticipated to allow for longer administration durations and slower infusion rates, potentially enabling clinicians to avoid reductions and safely achieve a higher dose intensity of pre-transplant chemotherapy. Spectrum Pharmaceuticals received FDA NDA approval in March 2016. We will submit import drug registration application for EVOMELA in greater China.

About Us

A leading US-headquartered, NASDAQ-listed, biopharmaceutical company targeting the global market, with a focus on China.

Learn More

In the News

CASI's turnaround turns eastward; firm seeks to be Celgene of China

Read Article →

Poster

Antitumor activity, safety and predictive biomarker results of ENMD-2076 administered to patients with recurrent ovarian clear cell carcinoma (OCCC): A trial of the Princess Margaret Phase II Consortium

Download →

Poster

Senescence as a Mechanism of Resistance to Aurora Kinase Inhibition with ENMD-2076 in p53 mutated Triple-Negative Breast Cancer (TNBC) Models

Download →